Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers.

导出原文传递

翻译打印收藏纠错

作者： Amichai,Perlman ^[1] ; Sarit,Hochberg-Klein ^[2] ; Lotan,Choshen Cohen ^[3] ; Gil,Dagan ^[2] ; Bruria,Hirsh-Raccah ^[4] ; Ehud,Horwitz ^[2] ; Gefen,Aldouby-Bier ^[2] ; Tamar,Negev ^[1] ; Ilan,Matok ^[3] ; Laurent,Azoulay ^[5] ; Yosef,Kalish ^[1] ; Mordechai,Muszkat ^[2]

作者单位： Pharmacy Division, Hadassah Hebrew University Medical Center, Jerusalem, Israel. ^[1] Department of Medicine, Hadassah Hebrew University Medical Center, Mt Scopus, 91540, Jerusalem, Israel. ^[2] Division of Clinical Pharmacy, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. ^[3] Department of Epidemiology, Biostatistics, and Occupational Health, Centre for Clinical Epidemiology, Jewish General Hospital, Lady Davis Institute, Montreal, Canada. ^[4] Department of Cardiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. ^[5] Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. ^[6] Department of Orthopedics, Hadassah Hebrew University Medical Center, Jerusalem, Israel. ^[7] Gerald Bronfman Department of Oncology, McGill University, Montreal, Canada. ^[8] Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. ^[9] Department of Medicine, Hadassah Hebrew University Medical Center, Mt Scopus, 91540, Jerusalem, Israel. muszkatm@hadassah.org.il. ^[10]

关键词 Antiepileptics Apixaban Dabigatran Direct oral anticoagulants Drug interaction Inducers Rivaroxaban